Although double staining for CALML3 and Ki-67 has not yet been systematically performed in other cancers, our results in skin cancer are in good agreement with findings in cervical and prostate carcinoma as well as in breast cancer: In all cases, CALML3 was found to be strongly reduced in the tumors [1], [2]. The gene discussed is MKI67; the disease is prostate carcinoma.